Neurodegenerative disorders (NDs) such as Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies. © 2009 Bentham Science Publishers Ltd.

Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise / Mai, Antonello; Rotili, Dante; Valente, Sergio; Aleksey, Kazantsev. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 15:34(2009), pp. 3940-3957. [10.2174/138161209789649349]

Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise

MAI, Antonello;ROTILI, Dante;VALENTE, Sergio;
2009

Abstract

Neurodegenerative disorders (NDs) such as Huntington's disease, Alzheimer's disease, Parkinson disease, amyotrophic lateral sclerosis, spinal muscular atrophy, Friedreich's ataxia, and others are multi-factorial illnesses, in which many pathways (still poorly understood) act serially and in parallel to give a determined pathologic phenotype. Thus, presently there are no effective cures for these diseases. Some phenotypic as well as mechanistic features, common to the most of NDs, can be linked to epigenetic defects, that can lead to alteration of acetylation homeostasis and impairment of the histone acetyltransferase (HAT): histone deacetylase (HDAC) balance. Here we survey most of the recent applications of HDAC inhibitors in the cited NDs, and we make the point of our (up to now) knowledge about the involvement of singular HDAC/SIRT isoform in NDs and other CNS pathologies. © 2009 Bentham Science Publishers Ltd.
2009
alzheimer's disease; amyotrophic lateral sclerosis; epigenetics; friedreich's ataxia; hdac inhibitors; huntington's disease; neurodegenerative disorders; parkinson disease; spinal muscular atrophy
01 Pubblicazione su rivista::01a Articolo in rivista
Histone deacetylase inhibitors and neurodegenerative disorders: Holding the promise / Mai, Antonello; Rotili, Dante; Valente, Sergio; Aleksey, Kazantsev. - In: CURRENT PHARMACEUTICAL DESIGN. - ISSN 1381-6128. - 15:34(2009), pp. 3940-3957. [10.2174/138161209789649349]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/442678
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 70
  • ???jsp.display-item.citation.isi??? 69
social impact